SCHEMBL476456

SCHEMBL476456

NC(=O)c1cn(-c2ccccc2)c(-c2ccccc2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA2 P47869 7/20 0.63
GABRB2 P47870 7/20 0.63
CNR1 P21554 1/20 0.48
ALDH1A1 P00352 2/20 0.44
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
KDM4E B2RXH2 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
PKM P14618 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA2B P29275 1/20 0.43
ADORA1 P30542 1/20 0.43
KAT2B Q92831 1/20 0.43
TGFBR1 P36897 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26986774 0.87 GABRA2 (0.67) GABRA2GABRB2CNR1PTGS1PTGS2
SCHEMBL23505039 0.84 GABRA2 (0.68) GABRA2GABRB2CNR1PTGS2SMN1; SMN2
SCHEMBL28900272 0.83 GABRA2 (0.62) GABRA2GABRB2CNR1ALDH1A1SMN1; SMN2
SCHEMBL6499142 0.81 GABRA2 (0.65) GABRA2GABRB2CNR1PTGS1PTGS2
SCHEMBL12361904 0.79 NR1H2 (0.54) GABRA2GABRB2PTGS1PTGS2
SCHEMBL5782234 0.78 GABRA2 (0.57) GABRA2GABRB2CNR1ALDH1A1PTGS1
SCHEMBL5419709 0.78 GABRA2 (0.62) GABRA2GABRB2ALDH1A1PTGS1PTGS2
SCHEMBL23027867 0.78 GABRA2 (1.00) GABRA2GABRB2ALDH1A1PTGS2
SCHEMBL5781289 0.77 GABRA2 (0.56) GABRA2GABRB2CNR1ALDH1A1PTGS2
SCHEMBL13437647 0.76 GABRA2 (0.95) GABRA2GABRB2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411383-B1 DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 EP disclosed
US-8486971-B2 Derivatives of 3-alkoxy-4,5-diarylthiophene-2-carboxamide, preparation thereof, and therapeutic use thereof SANOFI (FR) 2013-07-16 US disclosed
EP-2324015-B1 THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2013-07-03 EP disclosed
US-8410137-B2 Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-04-02 US disclosed
US-20120115906-A1 DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-05-10 US disclosed
EP-2411383-A1 DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-02-01 EP disclosed
US-20110183960-A1 THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-28 US disclosed
EP-2324015-A2 THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-aventis (FR) 2011-05-25 EP disclosed
WO-2010109150-A1 DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-09-30 WO disclosed
WO-2010012964-A2 THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-02-04 WO disclosed
US-20080306115-A1 Midazole-4-Carboxamide Derivatives For Use As Cb1 Modulators ASTRAZENECA AB (SE) 2008-12-11 US disclosed
US-7462631-B2 Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof SANOFI-AVENTIS (FR) 2008-12-09 US disclosed
CN-101263134-A Imidazole-4-carboxamide derivatives as CB modulators ASTRAZENECA AB (SE) 2008-09-10 CN disclosed
EP-1940820-A1 MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS AstraZeneca AB (SE) 2008-07-09 EP disclosed
WO-2007031721-A1 MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS ASTRAZENECA AB (SE) 2007-03-22 WO disclosed
US-20060264470-A1 Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof SANOFI-AVENTIS (FR) 2006-11-23 US disclosed
EP-1678159-A2 THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF AS CANNABINOID CB-1 RECEPTOR ANTAGONISTS Sanofi-Aventis (FR) 2006-07-12 EP disclosed
WO-2005035488-A2 THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF AS CANNABINOID CB-1 RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306115-A1 Midazole-4-Carboxamide Derivatives For Use As Cb1 Modulators CNR2, CNR1, FAAH GABRA2 139/4885GABRB2 97/4885CNR1 2/4885
US-20060264470-A1 Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof CNR1, CNR2, TPMT GABRA2 3144/4885GABRB2 2730/4885CNR1 1/4885
US-20120115906-A1 DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF HRH4, HCRTR1, NR3C1 GABRA2 667/4885GABRB2 683/4885CNR1 4/4885
US-20110183960-A1 THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF NR3C2, NR1H3, NR1H2 GABRA2 489/4885GABRB2 470/4885CNR1 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.